The announcement of interim results from a significant trial such as the Phase III CardiAMP cell therapy heart failure trial can lead to increased volatility and investor concern, especially if the results do not meet investor expectations or if the market perceives the results as negative. This can lead to a short-term decrease in stock price as investors reassess the company's future prospects based on the new data.